Trillium Therapeutics Inc (TRIL)

[RockRat]

Well, I guess I lost our little side bet: Trillium is in fact presenting early data at ASCO:

<<Abstract TPS7585
A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory hematologic malignancies.

Poster Board: #134b
Stephen Maxted Ansell, MD - Presenter
Division of Hematology, Mayo Clinic<<

This is June 6th in the morning session.

Times are a-changing.

Regards, RockRat